{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.7","value":"15.2"}]}],"title":"Prior to vaccine administration (Week 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.0","value":"32.8"}]}],"title":"Prior to vaccine booster (Week 4)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.7","value":"11.1"}]}],"title":"After vaccine booster (Week 8)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Interleukin 6 (IL-6) concentration levels measures in peripheral blood. Increased levels of IL-6 is associated with associated with advanced disease and poor prognosis.","dispersionType":"Standard Deviation","groups":[{"description":"α DC1 Vaccine\n\nand\n\nChemokine Modulatory Regimen:\n\nCelecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \\& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\\^2 or 20 MU/m\\^2 (T-Fri)","id":"OG000","title":"α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen"}],"paramType":"MEAN","populationDescription":"Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for completing surgery and response to treatment, and with ≥80% of samples available with measurable cytokine profiles via peripheral blood assay.","reportingStatus":"POSTED","timeFrame":"Prior to vaccine administration (Week 1), prior to vaccine booster (Week 4) and after vaccine booster (Week 8)","title":"Interleukin 6 (IL-6) Cytokine Levels","type":"SECONDARY","unitOfMeasure":"pg/mL"}